Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-up

J.L. Mansi , D. Easton , U. Berger , J.-C. Gazet , H.T. Ford , D. Dearnaley , R.C. Coombes
{"title":"Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-up","authors":"J.L. Mansi ,&nbsp;D. Easton ,&nbsp;U. Berger ,&nbsp;J.-C. Gazet ,&nbsp;H.T. Ford ,&nbsp;D. Dearnaley ,&nbsp;R.C. Coombes","doi":"10.1016/0277-5379(91)90413-8","DOIUrl":null,"url":null,"abstract":"<div><p>Using an antiserum to epithelial membrane antigen we have screened multiple bone marrow aspirates from 350 patients with primary breast cancer taken at the time of initial surgery. 89 (25%) patients were found to have micrometastases and their presence was related to pathological size (<em>P</em> &lt; 0.01), the presence of peritumoral vascular invasion (<em>P</em> &lt; 0.001), and positive lymph nodes (<em>P</em> &lt; 0.005) but not menopausal status. At a median follow-up of 76 months (range 34–108) 107 patients had relapsed with distant metastases. 48% (43 of 89) of these patients had micrometastases initially compared with 25% (64 of 261) who did not (<em>P</em> &lt; 0.005). The test predicts for relapse in bone (<em>P</em> &lt; 0.01) and other distant sites excluding bone (<em>P</em> &lt; 0.001) and is associated with a shorter overall survival (<em>P</em> &lt; 0.005). We conclude that the detection of micrometastases signals a high likelihood of early relapse and decreased survival in breast cancer.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90413-8","citationCount":"201","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0277537991904138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 201

Abstract

Using an antiserum to epithelial membrane antigen we have screened multiple bone marrow aspirates from 350 patients with primary breast cancer taken at the time of initial surgery. 89 (25%) patients were found to have micrometastases and their presence was related to pathological size (P < 0.01), the presence of peritumoral vascular invasion (P < 0.001), and positive lymph nodes (P < 0.005) but not menopausal status. At a median follow-up of 76 months (range 34–108) 107 patients had relapsed with distant metastases. 48% (43 of 89) of these patients had micrometastases initially compared with 25% (64 of 261) who did not (P < 0.005). The test predicts for relapse in bone (P < 0.01) and other distant sites excluding bone (P < 0.001) and is associated with a shorter overall survival (P < 0.005). We conclude that the detection of micrometastases signals a high likelihood of early relapse and decreased survival in breast cancer.

原发性乳腺癌骨髓微转移:6年随访后的预后意义
我们使用抗上皮膜抗原血清筛选了350例初次手术时抽取的原发性乳腺癌患者的多次骨髓抽吸。89例(25%)患者发现微转移,其存在与病理大小有关(P <0.01),肿瘤周围血管侵犯的存在(P <0.001),淋巴结阳性(P <0.005),但与绝经期无关。在中位随访76个月(范围34-108)时,107例患者复发并发生远处转移。这些患者中48%(89人中43人)最初有微转移,而25%(261人中64人)没有微转移(P <0.005)。该试验预测骨复发(P <0.01)和其他远端部位(不包括骨)(P <0.001),并与较短的总生存期相关(P <0.005)。我们得出结论,微转移的检测表明乳腺癌早期复发和生存率降低的可能性很高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信